Respiratory viral infections in transplant recipients

Current Opinion in Organ Transplantation

Volumn 10, Issue 4, 2005, Pages 312-319

  Ison, Michael G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adenovirus; Human metapneumovirus; Influenza virus; Respiratory virus infection; Transplantation

Indexed keywords

AMANTADINE; CIDOFOVIR; GANCICLOVIR; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OSELTAMIVIR; PALIVIZUMAB; PLECONARIL; RIBAVIRIN; RIMANTADINE; RUPINTRIVIR; SIALIDASE INHIBITOR; VALGANCICLOVIR; VIDARABINE; ZANAMIVIR;

ADENOVIRUS; CORONAVIRUS; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFLUENZA; METAPNEUMOVIRUS; MORBIDITY; MORTALITY; ORGAN TRANSPLANTATION; RECIPIENT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; REVIEW; RISK FACTOR; RNA VIRUS INFECTION; VIREMIA; VIRUS REPLICATION;

EID: 28044461458     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/01.mot.0000186962.26493.31     Document Type: Review

References (105)

1. Sayegh MH, Carpenter CB. Transplantation 50 Years Later-Progress, Challenges, and Promises. N Engl J Med 2004; 351:2761-2766.
2. Dharnidharka VR, Stablein DM, Harmon WE. Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. Am J Transplant 2004; 4:384-389.
3. Ison MG, Hayden FG. Viral infections in immunocompromised patients: what's new with respiratory viruses? Curr Opin Infect Dis 2002; 15:355-367.
4. Nichols WG, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant 2001; 7(Suppl):11S-15S.
5. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004; 39:1300-1306. Case series of influenza infections among the hematopoietic stem cell transplant recipients at one center; detailed attention to risk factors, epidemiology, and clinical outcomes with and without therapy.
6. Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100:4358-4366.
7. Khalifah AP, Hachem RR, Chakinala MM, et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med 2004; 170:181-187. A prospective study that clearly demonstrated an association between respiratory viral infections and bronchiolitis obliterans syndrome.
8. Ison MG, Mills J, Openshaw P, et al. Current research on respiratory viral infections: Fifth International Symposium. Antiviral Res 2002; 55:227-78.
9. Ohm-Smith MJ, Nassos PS, Haller BL. Evaluation of the Binax NOW, BD Directigen, and BD Directigen EZ Assays for detection of respiratory syncytial virus. J Clin Microbiol 2004; 42:2996-2999.
10. Englund JA, Piedra PA, Jewell A, et al. Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults. J Clin Microbiol 1996; 34:1649-1653.
11. Machado CM, Boas LS, Mendes AV, et al. Use of oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transplant 2004; 34:111-114. Case series documenting the excellent clinical outcomes of oseltamivir to treat influenza in hematopoietic stem cell transplant recipients.
12. Monto A, Herlocker M, Rotthoff J,Bidol S. [abstract 888]. 39th Annual Meeting of the Infectious Diseases Society of America; 2001; San Francisco; 2001.
13. Rawlinson WD, Waliuzzaman ZM, Fennell M, et al. New point of care test is highly specific but less sensitive for influenza virus A and B in children and adults. J Med Virol 2004; 74:127-131.
14. Storch GA. Rapid diagnostic tests for influenza. Curr Opin Pediatr 2003; 15:77-84.
15. Wunderli W, Thomas Y, Muller DA, et al. Rapid antigen testing for the surveillance of influenza epidemics. Clin Microbiol Infect 2003; 9:295-300.
16. Weinberg A, Zamora MR, Li S, et al. The value of polymerase chain reaction for the diagnosis of viral respiratory tract infections in lung transplant recipients. J Clin Virol 2002; 25:171-175.
17. Liolios L, Jenney A, Spelman D, et al. Comparison of a multiplex reverse transcription-PCR-enzyme hybridization assay with conventional viral culture and immunofluorescence techniques for the detection of seven viral respiratory pathogens. J Clin Microbiol 2001; 39:2779-2783.
18. van Elden LJ, van Loon AM, van der Beek A, et al. Applicability of a real-time quantitative PCR assay for diagnosis of respiratory syncytial virus infection in immunocompromised adults. J Clin Microbiol 2003; 41:4378-4381.
19. van Elden LJ, van Kraaij MG, Nijhuis M, et al. Polymerase chain reaction is more sensitive than viral culture and antigen testing for the detection of respiratory viruses in adults with hematological cancer and pneumonia. Clin Infect Dis 2002; 34:177-183.
20. van Kraaij MG, van Elden LJ, van Loon AM, et al. Frequent detection of respiratory viruses in adult recipients of stem cell transplants with the use of real-time polymerase chain reaction, compared with viral culture. Clin Infect Dis 2005; 40:662-669. A prospective study using polymerase chain reaction (PCR) to detect respiratory viral infections in transplant recipients. This study is particularly important, because it is one of the first studies to use PCR to prospectively determine the epidemiology of respiratory viral infections.
21. Roghmann M, Ball K, Erdman D, et al. Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation. Bone Marrow Transplant 2003; 32:1085-1088.
22. Rovida F, Percivalle E, Zavattoni M, et al. Monoclonal antibodies versus reverse transcription-PCR for detection of respiratory viruses in a patient population with respiratory tract infections admitted to hospital. J Med Virol 2005; 75:336-347. A study comparing immunoassay with polymerase chain reaction for diagnosis of respiratory viral infections; similar sensitivity was noted.
23. Abdallah A, Rowland KE, Schepetiuk SK, et al. An outbreak of respiratory syncytial virus infection in a bone marrow transplant unit: effect on engraftment and outcome of pneumonia without specific antiviral treatment. Bone Marrow Transplant 2003; 32:195-203.
24. Hassan IA, Chopra R, Swindell R, Mutton KJ. Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie hospital experience. Bone Marrow Transplant 2003; 32:73-77. A single-center case series that demonstrated the epidemiology of respiratory viral infections in Europe.
25. Raboni SM, Nogueira MB, Tsuchiya LR, et al. Respiratory tract viral infections in bone marrow transplant patients. Transplantation 2003; 76:142-146.
26. Small TN, Casson A, Malak SF, et al. Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29:321-327.
27. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev 2000; 13:371-384.
28. Nichols WG, Corey L, Gooley T, et al. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001; 98:573-578.
29. Anonymous. Guidelines for preventing opportunistic infections among hematopoeitic stem cell transplant recipients. MMWR; 2000; 49 (RR-10). 1-147.
30. Dykewicz CA. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: focus on community respiratory virus infections. Biol Blood Marrow Transplant 2001; 7(Suppl):19S-22S.
31. Anaissie EJ, Mahfouz TH, Aslan T, et al. The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management. Blood 2004; 103:1611-1617. A natural history study of respiratory syncytial virus (RSV) in hematopoietic stem cell transplant (HSCT) recipients; most of the recipients were getting an autologous HSCT for multiple myeloma. The authors concluded that it was safe to proceed with HSCT despite isolation of RSV. They also demonstrated a higher rate of hypoxemia (23% versus 10%), respiratory failure (4% versus 2%), and death (5% versus 2%) in infected patients.
32. Peck AJ, Corey L, Boeckh M. Pretransplantation respiratory syncytial virus infection: impact of a strategy to delay transplantation. Clin Infect Dis 2004; 39:673-680. A prospective study that documented delay of hematopoietic stem cell transplantation secondary to respiratory syncytial virus (RSV) infection had no effect on 1-year survival compared with patients who were not infected with RSV and thus did not have a delay.
33. Lewinsohn DM, Bowden RA, Mattson D, Crawford SW. Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation. Antimicrob Agents Chemother 1996; 40:2555-2557.
34. Schleuning M, Buxbaum-Conradi H, Jager G, Kolb HJ. Intravenous ribavirin for eradication of respiratory syncytial virus (RSV) and adenovirus isolates from the respiratory and/or gastrointestinal tract in recipients of allogeneic hematopoietic stem cell transplants. Hematol J 2004; 5:135-144.
35. McCurdy LH, Milstone A, Dummer S. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant 2003; 22:745-753.
36. Cortez K, Murphy BR, Almeida KN, et al. Immune-globulin prophylaxis of respiratory syncytial virus infection in patients undergoing stem-cell transplantation. J Infect Dis 2002; 186:834-838.
37. Ottolini MG, Curtis SR, Mathews A, et al. Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model. Bone Marrow Transplant 2002; 29:117-120.
38. Boeckh M, Berrey MM, Bowden RA, et al. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis 2001; 184:350-354.
39. Flynn JD, Akers WS, Jones M, et al. Treatment of respiratory syncytial virus pneumonia in a lung transplant recipient: case report and review of the literature. Pharmacotherapy 2004; 24:932-938.
40. El Saleeby CM, Suzich J, Conley ME, DeVincenzo JP. Quantitative effects of palivizumab and donor-derived T cells on chronic respiratory syncytial virus infection, lung disease, and fusion glycoprotein amino acid sequences in a patient before and after bone marrow transplantation. Clin Infect Dis 2004; 39:e17-e20. A clinical study that attempted to determine the pharmacodynamics of palivizumab.
41. Vilchez RA, McCurry K, Dauber J, et al. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant 2002; 2:287-291.
42. Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res 2004; 103:199-203. A clear review of the known mechanisms of resistance in influenza infections.
43. Duchini A, Goss JA, Karpen S, Pockros PJ. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin Microbiol Rev 2003; 16:357-364.
44. Lawal A, Basler C, Branch A, et al. Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation. Am J Transplant 2004; 4:1805-1809.
45. Mazzone PJ, Mossad SB, Mawhorter SD, et al. Cell-mediated immune response to influenza vaccination in lung transplant recipients. J Heart Lung Transplant 2004; 23:1175-1181.
46. Magnani G, Falchetti E, Pollini G, et al. Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study. J Heart Lung Transplant 2005; 24:588-592.
47. Harper SA, Fukuda K, Uyeki TM, et al. Centers for Disease Control and Prevention Advisory Committee on Immunization P. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2004; 53:1-40. Current ACIP/CDC recommendations on influenza vaccine. Updated annual.
48. La Rosa AM, Malik S, Englund JA, et al. Influenza A in hospitalized adults with leukemia and hematopoietic stem cell transplant (HSCT) recipients: risk factors for progression to pneumonia [abstract 418]. 39th Infectious Diseases Society of America; San Francisco, CA: 2001.
49. Johny AA, Clark A, Price N, et al. The use of zanamivir to treat influenza A and B infection after allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 29:113-115.
50. Hayden FG. Combination antiviral therapy for respiratory virus infections. Antiviral Res 1996; 29:45-48.
51. Ison MG, Gnann JW Jr, Nagy-Agren S, et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 2003; 8:183-190.
52. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group [see comments]. JAMA 2000; 283:1016-1024.
53. Vilchez RA, Dauber J, McCurry K, et al. Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function. Am J Transplant 2003; 3:116-120.
54. Vilchez RA, McCurry K, Dauber J, et al. The epidemiology of parainfluenza virus infection in lung transplant recipients. Clin Infect Dis 2001; 33:2004-2008.
55. Humar A, Doucette K, Kumar D, et al. An assessment of adenovirus infection in adult lung transplant recipients using molecular surveillance methods [abstract 9000]. American Transplant Congress; Seattle, WA: 2005. Prospective study that demonstrated that 7.2% of solid organ transplant recipients had detectable adenoviremia in the first year after transplant. Few had symptoms attributable to adenovirus, and all cleared the virus without sequelae.
56. Humar A, Moussa G, Mazzulli T, et al. The PV 16000 Study Group. An assessment of adenovirus infection in a large cohort of solid organ transplant recipients [abstract 977]. American Transplant Congress; Boston, MA: 2004. Prospective study that demonstrated that 22.5% of solid organ transplant recipients had detectable adenoviremia in the first year after transplant. Few had symptoms attributable to adenovirus, and all cleared the virus without sequelae.
57. Walls T, Hawrami K, Ushiro-Lumb I, et al. Adenovirus infection after pediatric bone marrow transplantation: is treatment always necessary? Clin Infect Dis 2005; 40:1244-1249. A study that documented adenoviremia in 42% of pediatric hematopoietic stem cell transplant recipients; not all cleared the virus without therapy.
58. Seidemann K, Heim A, Pfister ED, et al. Monitoring of adenovirus infection in pediatric transplant recipients by quantitative PCR: report of six cases and review of the literature. Am J Transplant 2004; 4:2102-2108.
59. Kaneko H, Mori S, Suzuki O, et al. The cotton rat model for adenovirus ocular infection: antiviral activity of cidofovir. Antiviral Res 2004; 61:63-66.
60. Mentel R, Kinder M, Wegner U, et al. Inhibitory activity of 3′-fluoro-2′ deoxythymidine and related nucleoside analogues against adenoviruses in vitro. Antiviral Res 1997; 34:113-119.
61. Mentel R, Wegner U. Evaluation of the efficacy of 2′,3′- dideoxycytidine against adenovirus infection in a mouse pneumonia model. Antiviral Res 2000; 47:79-87.
62. Smith KO, Galloway KS, Kennell WL, et al. A new nucleoside analog, 9-[[2-hydroxy-1-(hydroxymethyl)ethoxyl]methyl]guanine, highly active in vitro against herpes simplex virus types 1 and 2. Antimicrob Agents Chemother 1982; 22:55-61.
63. Ljungman P. Treatment of adenovirus infections in the immunocompromised host. Eur J Clin Microbiol Infect Dis 2004; 23:583-588. A clear review of therapeutic options the management of adenovirus.
64. Bruno B, Gooley T, Hackman RC, et al. Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival. Biol Blood Marrow Transplant 2003; 9:341-352.
65. Morfin F, Dupus-Girod S, Carrington D, Sedlacek P, et al. (Abstract V-282). Adenovirus susceptibility to antiviral drugs is genogroup-dependent. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL. 2003.
66. Lankester AC, Heemskerk B, Claas EC, et al. Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection. Clin Infect Dis 2004; 38:1521-1525. A landmark prospective study that failed to demonstrate antiviral effect of ribavirin in vivo against adenovirus.
67. Hoffman JA, Shah AJ, Ross LA, Kapoor N. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7:388-394.
68. Hatakeyama N, Suzuki N, Kudoh T, et al. Successful cidofovir treatment of adenovirus-associated hemorrhagic cystitis and renal dysfunction after allogenic bone marrow transplant. Pediatr Infect Dis J 2003; 22:928-929.
69. Nagafuji K, Aoki K, Henzan H, et al. Cidofovir for treating adenoviral hemorrhagic cystitis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2004; 34:909-914. A case series of successful therapy of adenovirus hemorrhagic cystitis in hematopoietic stem cell transplant recipients.
70. Fanourgiakis P, Georgala A, Vekemans M, et al. Intravesical instillation of cidofovir in the treatment of hemorrhagic cystitis caused by adenovirus type 11 in a bone marrow transplant recipient. Clin Infect Dis 2005; 40:199-201.
71. Leruez-Ville M, Minard V, Lacaille F, et al. Real-time blood plasma polymerase chain reaction for management of disseminated adenovirus infection. Clin Infect Dis 2004; 38:45-52. Groundbreaking prospective case series of polymerase chain reaction monitoring of clinical response to cidofovir in hematopoietic stem cell transplant recipients with disseminated adenoviral infection. Most patients had clinical response; of those who did not, lack of response was noted early in the treatment course.
72. Hartline CB, Gustin KM, Wan WB, et al. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis 2005; 191:396-399. In-vitro data demonstrating the efficacy of lipid ester prodrugs of nucleoside phosphonates against adenovirus.
73. Ison MG, Hayden FG, Kaiser L, et al. Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia. Clin Infect Dis 2003; 36:1139-1143.
74. Ghosh S, Champlin R, Couch R, et al. Rhinovirus infections in myelosuppressed adult blood and marrow transplant recipients. Clin Infect Dis 1999; 29:528-532.
75. Rabella N, Rodriguez P, Labeaga R, et al. Conventional respiratory viruses recovered from immunocompromised patients: clinical considerations. Clin Infect Dis 1999; 28:1043-1048.
76. Wasserman R, August CS, Plotkin SA. Viral infections in pediatric bone marrow transplant patients. Pediatr Infect Dis J 1988; 7:109-115.
77. Bowden RA. Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience. Am J Med 1997; 102:27-30; discussion 42-23.
78. Crooks BN, Taylor CE, Turner AJ, et al. Respiratory viral infections in primary immune deficiencies: significance and relevance to clinical outcome in a single BMT unit. Bone Marrow Transplant 2000; 26:1097-1102.
79. Hayden FG, Coats T, Kim K, et al. Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in phase II clinical trials. Antivir Ther 2002; 7:53-65.
80. Hayden FG, Herrington DT, Coats TL, et al. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis 2003; 36:1523-1532.
81. Hamelin ME, Abed Y, Boivin G. Human metapneumovirus: a new player among respiratory viruses. Clin Infect Dis 2004; 38:983-990. A concise review of human metapneumovirus epidemiology, clinical presentation, and outcomes.
82. van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001; 7:719-724.
83. van den Hoogen BG, Osterhaus DM, Fouchier RA. Clinical impact and diagnosis of human metapneumovirus infection. Pediatr Infect Dis J 2004; 23:S25-S32.
84. Cote S, Abed Y, Boivin G. Comparative evaluation of real-time PCR assays for detection of the human metapneumovirus. J Clin Microbiol 2003; 41:3631-3635.
85. Deffrasnes C, Cote S, Boivin G. Analysis of replication kinetics of the human metapneumovirus in different cell lines by real-time PCR. J Clin Microbiol 2005; 43:488-490.
86. Esper F, Boucher D, Weibel C, et al. Human metapneumovirus infection in the United States: clinical manifestations associated with a newly emerging respiratory infection in children. Pediatrics 2003; 111:1407-1410.
87. Mackay IM, Jacob KC, Woolhouse D, et al. Molecular assays for detection of human metapneumovirus. J Clin Microbiol 2003; 41:100-105.
88. Maertzdorf J, Wang CK, Brown JB, et al. Real-time reverse transcriptase PCR assay for detection of human metapneumoviruses from all known genetic lineages. J Clin Microbiol 2004; 42:981-986.
89. Greensill J, McNamara PS, Dove W, et al. Human metapneumovirus in severe respiratory syncytial virus bronchiolitis. Emerg Infect Dis 2003; 9:372-375.
90. Semple MG, Cowell A, Dove W, et al. Dual infection of infants by human metapneumovirus and human respiratory syncytial virus is strongly associated with severe bronchiolitis. J Infect Dis 2005; 191:382-386.
91. Boivin G, Abed Y, Pelletier G, et al. Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis 2002; 186:1330-1334.
92. Cane PA, van den Hoogen BG, Chakrabarti S, et al. Human metapneumovirus in a haematopoietic stem cell transplant recipient with fatal lower respiratory tract disease. Bone Marrow Transplant 2003; 31:309-310. Case report of fatal human metapneumovirus infection in a hematopoietic stem cell transplant recipient.
93. Levin MD, van Doornum GJ. An immunocompromised host with bilateral pulmonary infiltrates. Neth J Med 2004; 62:197, 210.
94. Pelletier G, Dery P, Abed Y, Boivin G. Respiratory tract reinfections by the new human metapneumovirus in an immunocompromised child. Emerg Infect Dis 2002; 8:976-978.
95. Wyde PR, Chetty SN, Jewell AM, et al. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res 2003; 60:51-59. In-vitro assessment of ribavirin and immunoglobulin against human metapneumovirus.
96. 3 against human metapneumovirus.
97. Folz RJ, Elkordy MA. Coronavirus pneumonia following autologous bone marrow transplantation for breast cancer. Chest 1999; 115:901-905.
98. Peiris JSM, Yuen KY, Osterhaus ADME, Stohr K. The severe acute respiratory syndrome. N Engl J Med 2003; 349:2431-2441. Review of the current understanding of sever acute respiratory syndrome epidemiology, diagnosis, and management.
99. Kumar D, Tellier R, Draker R, et al. Severe acute respiratory syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening. Am J Transplant 2003; 3:977-981. Case report of a liver transplant recipient who died of severe acute respiratory syndrome.
100. Lam MF, Ooi GC, Lam B, et al. An indolent case of severe acute respiratory syndrome. Am J Respir Crit Care Med 2004; 169:125-128. Case report of a hematopoietic stem cell transplant recipient who survived severe acute respiratory syndrome
101. Chui AK, Rao AR, Chan HL, Hui AY. Impact of severe acute respiratory syndrome on liver transplantation service. Transplant Proc 2004; 36:2302-2303.
102. Ljungman P. Respiratory virus infections in stem cell transplant patients: the European experience. Biol Blood Marrow Transplant 2001; 7(Suppl): 5S-7S.
103. DeVincenzo JP, Hirsch RL, Fuentes RJ, Top FH Jr. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - a compassionate use experience. Bone Marrow Transplant 2000; 25:161-165.
104. Ghosh S, Champlin RE, Ueno NT, et al. Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins. Bone Marrow Transplant 2001; 28:271-275.
105. Whimbey E, Champlin RE, Englund JA, et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 1995; 16:393-399.